Solid Biosciences Strengthens Management Team to Advance Programs for Duchenne Muscular Dystrophy
July 01, 2021 08:00 ET
|
Solid Biosciences Inc.
-Additional expertise expected to support attainment of key corporate goals- CAMBRIDGE, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company...
Solid Biosciences Reports Inducement Grant to New Chief Regulatory Officer
June 07, 2021 07:35 ET
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., June 07, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences Announces Appointment of Iman Barilero, PharmD, Ph.D., as Chief Regulatory Officer
June 07, 2021 07:30 ET
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., June 07, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences to Present at the Jefferies Virtual Healthcare Conference
May 26, 2021 07:30 ET
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences to Present at Upcoming Scientific Conferences
May 25, 2021 16:03 ET
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences Provides First Quarter 2021 Business Update and Financial Results
May 14, 2021 07:30 ET
|
Solid Biosciences Inc.
- Patients 7 and 8 dosed in IGNITE-DMD Phase I/II clinical trial under new clinical protocol and second-generation SGT-001 manufacturing process; patient 8 experienced a serious adverse event - -...
Solid Biosciences to Host First Quarter 2021 Financial Results and Business Update Call on May 14, 2021
May 11, 2021 08:00 ET
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences Highlights Expertise in AAV Gene Therapy with Multiple Abstracts to be Presented at the American Society of Gene & Cell Therapy 24th Annual Meeting
May 04, 2021 08:00 ET
|
Solid Biosciences Inc.
-Data from studies of novel AAV vectors and AAV immunology and an encore of 12-month safety, efficacy and patient-reported outcomes measurements from the ongoing IGNITE DMD trial of SGT001 to be...
Solid Biosciences to Participate in Virtual Fireside Chat at the Chardan 5th Annual Genetic Medicines Manufacturing Summit
April 20, 2021 07:30 ET
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences to Participate at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day
March 25, 2021 07:30 ET
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...